The market for type 1 diabetes treatments is expected to grow significantly by 2033.
Analytics firm GlobalData estimates that revenue could reach $9.9 billion, with the United States accounting for the majority.
Several new drugs are in development, particularly treatments that target the immune system.
Sanofi’s acquisition of the biotech company Provention Bio in 2023 is an example of this trend, focusing on both diabetes and autoimmune diseases, Le Journal de Montreal writes.
Also read: Eat chocolate before bed – it may help you sleep better
Differences in approval
There are differences in how the treatment is approved internationally. In the EU, the drug was approved in January for children from the age of eight under the name Teizeild.
In the United States, the same treatment had previously also been limited to children aged eight and older.
It is administered via infusion and does not cure the disease, but works by suppressing the body’s immune response.
In this way, the progression of the disease can be slowed before symptoms appear.
Also read: How chocolate can affect your body if you eat it every day
New approval
Type 1 diabetes develops in several stages, and early treatment can have a significant impact. Young children in particular are at risk of rapid disease progression.
U.S. authorities have now expanded the approval of the treatment Tzield to include children from one year of age.
The goal is to delay the stage at which patients require insulin therapy.
Sources: Le Journal de Montreal and GlobalData.
Also read: New study: You can build strength without intense workouts
Also read: Animal-assisted therapy can improve your mental health